Bitget Lists Fabric Protocol (ROBO) for Spot Trading

VICTORIA, Seychelles, March 01, 2026 (GLOBE NEWSWIRE) — Bitget, the world's largest Universal Exchange (UEX), announced the addition of Fabric Protocol (ROBO) in the Innovation and AI Zone for spot trading. Trading for the ROBO/USDT pair opens on February 27, 2026, 10:00 (UTC), with withdrawals available from February 28, 2026, 11:00 (UTC). Fabric Protocol is […]

Bitget Lists Fabric Protocol (ROBO) for Spot Trading

Bitget Lists Fabric Protocol (ROBO) for Spot Trading GlobeNewswire March 02, 2026 VICTORIA, Seychelles, March 01, 2026 (GLOBE NEWSWIRE) — Bitget, the world's largest Universal Exchange (UEX), announced the addition of Fabric Protocol (ROBO) in the Innovation and AI Zone for spot trading. Trading for the ROBO/USDT pair opens on February 27, 2026, 10:00 (UTC),

Bitget Publishes February 2026 Proof of Reserves, Maintaining 169% Total Reserve Ratio

VICTORIA, Seychelles, March 01, 2026 (GLOBE NEWSWIRE) — Bitget, the world's largest Universal Exchange (UEX), has released its February 2026 Proof of Reserves (PoR), reaffirming full backing of user assets amid continued market volatility and cautious investor sentiment across digital asset markets. The February snapshot covers BTC, ETH, USDT, and USDC, with corresponding reserve data

Bitget Publishes February 2026 Proof of Reserves, Maintaining 169% Total Reserve Ratio

Bitget Publishes February 2026 Proof of Reserves, Maintaining 169% Total Reserve Ratio GlobeNewswire March 02, 2026 VICTORIA, Seychelles, March 01, 2026 (GLOBE NEWSWIRE) — Bitget, the world's largest Universal Exchange (UEX), has released its February 2026 Proof of Reserves (PoR), reaffirming full backing of user assets amid continued market volatility and cautious investor sentiment across

Bitget and Obside Partner to Launch Live AI Trading Arena for Copy Trading

VICTORIA, Seychelles, March 01, 2026 (GLOBE NEWSWIRE) — Bitget, the world's largest Universal Exchange (UEX), today announced a partnership with Obside, bringing the AI Trading Arena to Bitget through copy trading. Developed by Obside, the AI Trading Arena is a live environment where advanced AI models trade real markets autonomously using real-time data. The collaboration

Bitget and Obside Partner to Launch Live AI Trading Arena for Copy Trading

Bitget and Obside Partner to Launch Live AI Trading Arena for Copy Trading GlobeNewswire March 02, 2026 VICTORIA, Seychelles, March 01, 2026 (GLOBE NEWSWIRE) — Bitget, the world's largest Universal Exchange (UEX), today announced a partnership with Obside, bringing the AI Trading Arena to Bitget through copy trading. Developed by Obside, the AI Trading Arena

SynaXG Proves the Art of the Possible with Fully Software-Defined AI-RAN on NVIDIA AI Aerial

BARCELONA, Spain and SINGAPORE, March 02, 2026 (GLOBE NEWSWIRE) — SynaXG today announced major technical breakthroughs in AI-native radio access networks, demonstrating concurrent operation of 5G FR1, 5G FR2 and AI workloads on NVIDIA AI-RAN platform with real-time, policy-driven GPU orchestration. The results confirm that software-defined, AI-native RAN can deliver carrier-grade performance and continuous 24×7

SynaXG Proves the Art of the Possible with Fully Software-Defined AI-RAN on NVIDIA AI Aerial

SynaXG Proves the Art of the Possible with Fully Software-Defined AI-RAN on NVIDIA AI Aerial Achieves benchmark 5G vRAN performance on FR1 and FR2, with seamless orchestration between AI and RAN workloads GlobeNewswire March 02, 2026 BARCELONA, Spain and SINGAPORE, March 02, 2026 (GLOBE NEWSWIRE) — SynaXG today announced major technical breakthroughs in AI-native radio

InnoCare’s next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China

(HKSE:9969), BEIJING, March 01, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that its next generation TRK inhibitor zurletrectinib (ICP-723) has been granted priority review by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA), for

InnoCare’s next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China

InnoCare's next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China GlobeNewswire March 02, 2026 BEIJING, March 01, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that its next generation TRK inhibitor zurletrectinib (ICP-723)

Scroll to Top